Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133522 | 1.00 | PDE5A (0.70) | PDE5AKCNH2 | |
| SCHEMBL4038540 | 1.00 | PDE5A (0.70) | PDE5AKCNH2 | |
| Hydrochloric Acid SCHEMBL5430308 | 0.99 | PDE5A (0.70) | PDE5AKCNH2 | |
| SCHEMBL8301267 | 0.95 | PDE5A (0.63) | PDE5AKCNH2 | |
| SCHEMBL12768975 | 0.94 | PDE5A (0.63) | PDE5AKCNH2 | |
| SCHEMBL4037727 | 0.94 | PDE5A (0.62) | PDE5AKCNH2 | |
| SCHEMBL12768986 | 0.92 | PDE5A (0.68) | PDE5AKCNH2 | |
| SCHEMBL13805635 | 0.92 | PDE5A (0.68) | PDE5AKCNH2 | |
| SCHEMBL4218212 | 0.92 | PDE5A (0.68) | PDE5AKCNH2 | |
| SCHEMBL13805627 | 0.90 | PDE5A (0.56) | PDE5AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | claimed |
| EP-1601673-B1 | FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | EP | claimed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | claimed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | ABCB11, PCSK9, SLC10A1 | PDE5A 103/4885KCNH2 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.